alternatives to glp-1 agonists comparison of glp 1 Receptor Agonists: An Alternative for Rapid-Acting Insulin? New research from @doctorsigh shows
Description
In total, 86.4% of the semaglutide group lost a minimum of 5% of their body weight, with minimal adverse effects
Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines
2025;8:e2457349
8,9,37 These data provide robust evidence for the benefit of tirzepatide in patients with obesity and HFpEF
[DOI] [PMC free article] [PubMed] [Google Scholar] 124.Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, et al
35 and Sedam et al
